Summary of COVID-19 resveratrol studies

1. McCreary et al., Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)

100 patient resveratrol early treatment RCT: 67% lower hospitalization (p=0.62) and 43% lower progression (p=0.52).
RCT 100 outpatients in the USA, showing lower hospitalization and progression with resveratrol, without statistical significance.
Jun 2022, Scientific Reports, https://www.nature.com/articles/s41598-022-13920-9, https://c19p.org/mccreary3

2. Mittra et al., Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)

230 patient resveratrol late treatment study: 44% lower mortality (p=0.06).
Retrospective 230 severe COVID-19 patients in India, showing lower mortality with resveratrol + copper, without statistical significance. This study followed preclinical data showing that sepsis-related cytokine storm and fatality in mice could be prevented with oral administration of resveratrol and copper.
Jul 2020, medRxiv, https://www.medrxiv.org/content/10.1101/2020.07.21.20151423, https://c19p.org/mittra

3. Kaplan et al., Resveratrol and Zinc in the Treatment of Outpatients With COVID-19 – The Reszinate Study - A Phase 1/2 Randomized Clinical Trial Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling

30 patient resveratrol late treatment RCT: 14% higher ventilation (p=1), 14% higher ICU admission (p=1), and 14% higher hospitalization (p=1).
Small RCT of zinc plus resveratrol in COVID-19+ outpatients, showing no significant differences in viral clearance or symptoms. Although the treatment group was older (46.3 vs. 38.5) and had more severe baseline symptoms, they had similar symptomatic recovery by the second week.
Sep 2021, SSRN, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3934228, https://c19p.org/kaplanrsv